Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancer.

Hiroshi Saeki, Hidefumi Higashi, Shin Ichiro Maehara, Junko Tanaka, Ichiro Makino, Shigeru Imamura, Masakazu Aso, Hidenori Katoh, Yoshihiro Kakeji, Yoshihiko Maehara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

PURPOSE: Oxaliplatin, Irinotecan, 5-fluorouracil and leucovorin are commonly used to treat advanced colorectal cancer in Western countries. Here, we investigated the efficacy and safety of FOLFOX/FOLFIRI in Japanese colorectal cancer patients. METHODS: FOLFOX4, modified FOLFOX6 and FOLFIRI was administered to a total of 23 patients with far advanced or recurrent colorectal cancer in our institute. Tumor response rate and toxicity were analyzed with these patients. RESULTS: Partial response and stable disease was observed in 28.6% of patients, respectively. There was no therapy-related death. Neutropenia was observed in 12 cases (52.2%), anemia was in 12 cases (52.2%) and thrombocytopenia was in 6 cases (26.1%), respectively; among them, 9 patients (39.1%) experienced a Grade 3 of bone marrow suppression. Fatigue was observed in 8 cases (34.8%), nausea/vomiting was in 4 cases (17.4%), diarrhea was in 4 cases (17.4%) and neurotoxicity was in 8 cases (34.8%), respectively. All nonhematological toxicities were Grade 1 or 2. CONCLUSION: FOLFOX/FOLFIRI can contribute to efficacy and safety in cases of advanced colorectal cancer. In order to evaluate the long-term clinical results in Japanese patients, prospective controlled studies are urgently called for.

Original languageEnglish
Pages (from-to)253-259
Number of pages7
JournalFukuoka igaku zasshi = Hukuoka acta medica
Volume98
Issue number6
Publication statusPublished - Jan 1 2007

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Saeki, H., Higashi, H., Maehara, S. I., Tanaka, J., Makino, I., Imamura, S., ... Maehara, Y. (2007). Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancer. Fukuoka igaku zasshi = Hukuoka acta medica, 98(6), 253-259.